Clinical Efficacy of Intravitreal Injection of Conbercept in the Treatment of PM-CNV and Its Impact on Macular Morphology and Microcirculation
Objective:To investigate the clinical efficacy of intravitreal injection of Conbercept in the treatment of pathological myopia secondary choroidal neovascularization (PM-CNV) and its effects on macular morphology and microcirculation. Method:A total of 101 patients with PM-CNV admitted to the First Affiliated Hospital of Bengbu Medical University from June 2021 to March 2024 were selected and divided into two groups according to different treatment methods. The control group (n=49) was treated with intravitreal injection of Ranibizumab,while the observation group (n=52) was treated with intravitreal injection of Conbercept. The best corrected visual acuity (BCVA),intraocular pressure,macular morphology indicators[central macular thickness (CMT),subfoveal inner retina thickness (IRT),subfoveal outer retina thickness (ORT)],microcirculation indicators[superficial capillary plexus vessel density (SCP-VD),deep capillary plexus vessel density (DCP-VD),foveal vessel density (FVD),choroidal capillary vessel density (CC-VD)]before and after treatment,and incidence of complications between two groups. Result:After treatment,the logMAR BCVA,intraocular pressure,CMT,IRT,ORT and CC-VD in observation group were lower than those in control group,while SCP-VD,DCP-VD and FVD were higher than those in control group,with statistical significance (P<0.05). The incidence of complications in the observation group (3.85％) was lower than that in the control group (16.33％),the difference was statistically significant (P<0.05). Conclusion:Intravitreal injection of Conbercept in the treatment of PM-CNV can promote visual acuity recovery,improve macular morphology and microcirculation,with low complication rate and good safety.
Pathological myopiaSecondary choroidal neovascularizationIntravitreal injection of ConberceptMacular morphologyMicrocirculation
万方数据
维普
